Grant: Collaborative Research and Development Grants
Université de Montréal
$114,949.00
Development of a sub-unit vaccine to protect swine against the infections caused by Streptococcus suis
FY 2015-16
Summary
Streptococcus suis is one of the most important causes of bacterial disease in post-weaned piglets. Affected animals suffer from meningitis (affected brain), endocarditis (affected heart), arthritis (affected joints) and septicemia (general infection). There are 35 serotypes of S. suis (same bacteria but different antigens). Some of these serotypes (such as serotype 2) can also affect humans (transmission from pigs), causing serious disease. Usually, veterinarians use antibiotics to treat and even protect animals. However, the large use of antibiotic induces the increase of antibiotic-resistance and there are now many S. suis bacterial strains that are resistant. Unfortunately, there are no effective vaccines in the market to protect against this infection. We have identified a protein called ""Sao"" that protects pigs against a bacterial strain of S. suis serotype 2. It is not known if it protects against other strains and other serotypes that cause disease in pigs. Production of Sao protein should also be improved to obtain acceptable yields to have enough material to be tested in a large vaccine trial. In addition, this protein should be mixed with a very good pharmacological agent that increase or aid the immune response of animals (called ""adjuvant""). A good adjuvant for Sao protein that is allowed to be commercially used in pigs needs to be found.
The general objective of this project is to obtain a reliable Sao-adjuvant prototype vaccine that will protect pigs against most serotypes of S. suis. In addition, and to complete the vaccine, other proteins already identified by our laboratory will be tested and incorporated into the vaccine. At the end of the project we will have a vaccine prototype composed by Sao combined with other protein(s) with an appropriate adjuvant.
Program
Collaborative Research and Development Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
468787-2014
Name nom
Gottschalk, Marcelo
Department département
Pathologie et microbiologie
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
114949
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
100
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Agriculture and primary food production
Area of application fr
Agriculture et produits alimentaires primaires
Research subject code
5512
Research subject group en
Animal biology
Research subject group fr
Biologie animale
Research subject en
Veterinary sciences
Research subject fr
Médecine vétérinaire
Partie
1
Nb partie
3
Application title
Development of a sub-unit vaccine to protect swine against the infections caused by Streptococcus suis
Keyword
NSERC
Application summary
Streptococcus suis is one of the most important causes of bacterial disease in post-weaned piglets. Affected animals suffer from meningitis (affected brain), endocarditis (affected heart), arthritis (affected joints) and septicemia (general infection). There are 35 serotypes of S. suis (same bacteria but different antigens). Some of these serotypes (such as serotype 2) can also affect humans (transmission from pigs), causing serious disease. Usually, veterinarians use antibiotics to treat and even protect animals. However, the large use of antibiotic induces the increase of antibiotic-resistance and there are now many S. suis bacterial strains that are resistant. Unfortunately, there are no effective vaccines in the market to protect against this infection. We have identified a protein called ""Sao"" that protects pigs against a bacterial strain of S. suis serotype 2. It is not known if it protects against other strains and other serotypes that cause disease in pigs. Production of Sao protein should also be improved to obtain acceptable yields to have enough material to be tested in a large vaccine trial. In addition, this protein should be mixed with a very good pharmacological agent that increase or aid the immune response of animals (called ""adjuvant""). A good adjuvant for Sao protein that is allowed to be commercially used in pigs needs to be found.
The general objective of this project is to obtain a reliable Sao-adjuvant prototype vaccine that will protect pigs against most serotypes of S. suis. In addition, and to complete the vaccine, other proteins already identified by our laboratory will be tested and incorporated into the vaccine. At the end of the project we will have a vaccine prototype composed by Sao combined with other protein(s) with an appropriate adjuvant.